JNJ-55308942 (JNJ55308942)
- Product Name
- JNJ-55308942 (JNJ55308942)
- CAS No.
- 2166558-11-6
- Chemical Name
- JNJ-55308942 (JNJ55308942)
- Synonyms
- JNJ-55308942, 10 mM in DMSO;JNJ-55308942 (JNJ55308942)
- CBNumber
- CB74844940
- Molecular Formula
- C17H12F5N7O
- Formula Weight
- 425.32
- MOL File
- 2166558-11-6.mol
JNJ-55308942 (JNJ55308942) Property
- storage temp.
- Store at -20°C
- solubility
- DMSO : 250 mg/mL (587.79 mM; Need ultrasonic)
- form
- Solid
- color
- White to light yellow
JNJ-55308942 (JNJ55308942) Chemical Properties,Usage,Production
Biological Activity
JNJ-55308942 is a high-affinity, selective, brain-penetrant P2X7 functional antagonist (hP2X7: IC50=10 nM, Ki=7.1 nM; rP2X7: IC50=15 nM, Ki=2.9 nM). JNJ-55308942 is orally bioavailable, binds to brain P2X7 and blocks IL-1β release from adult rodent brain[1][2]. JNJ-55308942 shows pKis of 8.1and 8.5 for recombinant human and rat P2X7 channels, respectively. In human blood and in mouse blood and microglia, JNJ-55308942 attenuates IL-1β release in a potent and concentration-dependent manner[2]. JNJ-55308942 (30 mg/kg; p.o.) attenuates LPS-induced microglial activation in mice[2].In a model of Bacillus Calmette-Guerin (BCG)-induced depression, JNJ-55308942 dosed orally (30 mg/kg), reversed the BCG-induced deficits of sucrose preference and social interaction. After oral dosing, the compound exhibited both dose and concentration-dependent occupancy of rat brain P2X7 with an ED50 of 0.07 mg/kg. The P2X7 antagonist (3 mg/kg, oral) blocked Bz-ATP-induced brain IL-1β release in conscious rats, demonstrating functional effects of target engagement in the brain[2]. JNJ-55308942 (5 mg/kg; p.o.) shows the F, Vss, CL, Cmax and AUC24h values are 81%, 1.7 L/kg, 3.7 mL min/kg, 1747 ng/mL, and 17549 (ng/mL) h, respectively[1].
References
[1]. Bhattacharya A, et al. Neuropsychopharmacology of JNJ-55308942: evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia. Neuropsychopharmacology. 2018;43(13):2586-2596. [2]. Chrovian CC, et al. A Dipolar Cycloaddition Reaction To Access 6-Methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridines Enables the Discovery Synthesis and Preclinical Profiling of a P2X7 Antagonist Clinical Candidate. J Med Chem. 2018;61(1):207-223.
JNJ-55308942 (JNJ55308942) Preparation Products And Raw materials
Raw materials
Preparation Products
JNJ-55308942 (JNJ55308942) Suppliers
- Tel
- +1-781-999-5354 +1-00000000000
- marketing@targetmol.com
- Country
- United States
- ProdList
- 32161
- Advantage
- 58
- Tel
- 027-87747081 18186681184
- 1344475572@qq.com
- Country
- China
- ProdList
- 7235
- Advantage
- 58
- Tel
- 1701086315
- Fax
- 1701086315@qq.com
- dexuanpharma@126.com
- Country
- China
- ProdList
- 9475
- Advantage
- 58
- Tel
- 027-59101668 19945030958
- Fax
- 027-59101668
- 2881924765@qq.com
- Country
- China
- ProdList
- 7921
- Advantage
- 58
- Tel
- 4008200310
- marketing@tsbiochem.com
- Country
- China
- ProdList
- 24644
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Country
- China
- ProdList
- 11974
- Advantage
- 58
- Tel
- 021-59167510 18117107507
- vip@med-life.cn
- Country
- China
- ProdList
- 4997
- Advantage
- 58
- Tel
- 025-85560043 15850508050
- Fax
- 025-85563444
- cindy.huang@synzest.com
- Country
- China
- ProdList
- 12000
- Advantage
- 58
- Tel
- 18024082417
- market@ubiochem.com
- Country
- China
- ProdList
- 9266
- Advantage
- 58
- Tel
- sangon@qq.com
- Country
- CHINA
- ProdList
- 47239
- Advantage
- 58